A Strategy Utilizing Protein-Protein Interaction Hubs for the Treatment of Cancer Diseases

Area of Science:

• Oncology
• Systems Biology
• Network Medicine

Background:

• Neoplastic diseases, particularly cancer, exhibit complex molecular interactions within a tumor's interactome.
• Scale-free network theory reveals that specific "hubs" are critical for network integrity and thus potential therapeutic targets.
• Understanding these network vulnerabilities is key to developing more effective and rational cancer therapies.

Purpose of the Study:

• To propose and validate a systematic strategy for neoplastic disease therapy centered on targeting protein "hubs" within tumor interactomes.
• To explore drug repurposing and RNA interference (RNAi) as therapeutic modalities for both druggable and non-druggable hubs.
• To establish a framework for personalized oncology by identifying and targeting critical protein nodes for improved patient outcomes.

Main Methods:

• Identification and selection of up-regulated connectivity hubs in the tumor interactome.
• Drug repurposing for druggable hubs and RNA interference (RNAi) for non-druggable targets.
• Validation through in vitro experiments, tumor-on-a-chip models, in vivo studies, and clinical trials.

Main Results:

• Demonstrated that scale-free networks are susceptible to targeted attacks on connective hubs.
• Confirmed a negative correlation between malignant cell aggressivity and the number of targets required for maximal patient survival benefit.
• Identified potential for improved therapeutic outcomes by targeting additional proteins, including those not typically addressed by current drug treatments.

Conclusions:

• A rational, hub-targeting strategy can be developed for neoplastic disease therapy.
• Drug repurposing and RNA interference (RNAi) offer viable therapeutic options for critical protein hubs.
• This approach supports personalized oncology by tailoring treatments to individual tumor network vulnerabilities, potentially enhancing patient survival.